Compare STGW & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STGW | AMPH |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2006 | 2005 |
| Metric | STGW | AMPH |
|---|---|---|
| Price | $6.15 | $19.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | $8.39 | ★ $30.29 |
| AVG Volume (30 Days) | ★ 1.8M | 581.3K |
| Earning Date | 03-10-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.03 |
| Revenue | ★ $2,909,000,000.00 | $719,887,000.00 |
| Revenue This Year | $14.09 | $7.34 |
| Revenue Next Year | $2.59 | $4.81 |
| P/E Ratio | ★ N/A | $9.36 |
| Revenue Growth | ★ 2.39 | N/A |
| 52 Week Low | $4.03 | $17.03 |
| 52 Week High | $7.17 | $31.26 |
| Indicator | STGW | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 65.29 | 32.55 |
| Support Level | $4.94 | N/A |
| Resistance Level | $6.50 | $28.56 |
| Average True Range (ATR) | 0.33 | 1.09 |
| MACD | 0.13 | -0.09 |
| Stochastic Oscillator | 82.17 | 32.08 |
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.